A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

Summary

The study will consist of a Screening period (up to 14 days), a Treatment period, and a Follow-Up period. Sixteen subjects will be enrolled into two sequential dose cohorts - 10 or 30 mg (or matching placebo) across four study centers.

Timeline

Start

2011-05

Primary completion

2013-09

Completion

2013-09

Outcome

Outcome not reported

Stopped: “pending further evaluation”

Drugs

Indications